Discussion
death, OUD, overdose
This description of organizational factors associated with sites participating in the CTN0080 MOMs study assists in filling the current gap in knowledge regarding academic health and community SUD programs providing services to PPI with OUD. It provides a glimpse into differences among the way that these services are coordinated. More precisely, this analysis demonstrates the wealth of information that these comprehensive and experienced programs offer to furthering research on integrative/collaborative care models and methods for implementing expert recommendations for treating this population. For example, a post-hoc analysis is tentatively planned in the MOMs study to explore site characteristics associated with treatment outcome.Given that previous research has identified significant challenges facing PPI with OUD in accessing care, we find it encouraging that results from the PAASA indicate that study sites, which were selected in part because of the comprehensive nature of their services, offer many elements described in the coordinated collaborative care models proposed by expert consensus groups (The finding that most sites had very low rates of racial and ethnic minority patient populations is consistent with recent findings of disparity in receipt of MOUD, particularly buprenorphine, during pregnancy for persons of color compared with White, non-Hispanic individuals (Opioid overdose is a leading cause of death in PPI (The findings presented here have limitations. Most notably, the 13 sites participating in CTN0080 MOMs were chosen in large part due to their strong collaborative care model, significant treatment resources, and experience with clinical trials; we do not know to what extent they represent other programs in the United States that are treating the population of PPI with OUD. Further, the sample size is small (